Skip to content
Buy This GLP
← Research
Evidence

Are GLP-1 Drugs Prescribed Off-Label? What the Records Show

Prescriptions rose after PCOS diagnosis, around childbirth, and among young people. The records cannot show which prescriptions were off-label.

Editorial profile: Carla MedinaBuy This GLP Editorial Team9 min read
Started within a year of PCOS diagnosis0.14%5.97%20182024Only 11.5% of those women had coded type 2 diabetes.The chart shows the two reported endpoints.

The term off-label describes an approved drug used outside its approved labeling [4]. The product, intended use and patient population all matter. A missing diabetes diagnosis alone cannot tell you whether a prescription was off-label. Some products are approved for weight management.

Prescribing after a PCOS diagnosis

Studies of GLP-1 treatment and PCOS ask a different question from the studies that count prescriptions. In one Polish private network, 5.97% of women diagnosed with PCOS in 2024 started an incretin drug within a year, up from 0.14% in 2018. Each later calendar year was associated with higher odds of starting treatment (adjusted odds ratio 1.64, 95% CI 1.56–1.73) [1].

Across the cohort, 11.5% of incretin users had coded type 2 diabetes and 75.5% also had a record of metformin exposure. Incretin users had a higher median BMI than women who took only metformin or received neither treatment. These records describe prescribing patterns and cannot establish effects on ovulation, fertility or other PCOS outcomes [1].

Use around childbirth and among young people

A U.S. study found that prescribing in the year after delivery rose from 0.3 to 14.6 per 1,000 deliveries between 2019 and 2024. The year before delivery includes time before pregnancy, so prescriptions recorded during that window cannot all be attributed to use in pregnancy [2].

Danish registry data showed 418 new users per 100,000 people aged 12 to 24 in 2025, up from 8.4 in 2018. The study attributed much of the growth to semaglutide for weight management. To study how long people stay on a GLP-1, the researchers measured how long prescriptions covered patients. They found that 38% still had coverage after a year, but the records could not explain why people stopped[3].

Frequently asked

What does off-label prescribing mean?
It means prescribing an approved drug in a way its approved labeling does not cover, such as for a different condition or patient population.
Does a missing diabetes diagnosis make a GLP-1 prescription off-label?
A diabetes diagnosis code alone cannot answer that. Some products are approved for weight management, and these data did not establish the indication for each prescription.

Sources

  1. [1] Dziewierz A, Kulicka N, Stolarska K, Ahmatovic A, Domienik-Karłowicz J (2026). Temporal Trends and Clinical Characteristics of Incretin-Based Therapy Use in Women With Polycystic Ovary Syndrome: A Real-World Cohort Study From a Polish Private Healthcare Network Diabetes, Obesity & Metabolism. PMID 42297761
  2. [2] Lessard C, Cary C, In A, Steinle J, et al. (2026). Prescribing Trends in Glucagon-Like Peptide-1 Medications Among Pregnant and Postpartum Persons Obstetrics and Gynecology. PMID 41505759
  3. [3] Kildegaard H, Andersen JH, Vinding RK, Kloppenborg JT, Pottegård A (2026). Use of Glucagon-Like Peptide-1 Receptor Agonists in Danish Adolescents and Young Adults 2018-2025 Obesity (Silver Spring, Md.). PMID 42252120
  4. [4] U.S. Food and Drug Administration (2018). Understanding Unapproved Use of Approved Drugs Off Label FDA. Source

Where to get it

GLP-1 telehealth prescribers

The sellers whose own pricing describes an ongoing prescribed plan, rather than a checkout that assumes you already have a script.

See the board →

More in Evidence